Morgan Stanley Maintains CRISPR Therapeutics(CRSP.US) With Sell Rating, Maintains Target Price $45
A Quick Look at Today's Ratings for CRISPR Therapeutics(CRSP.US), With a Forecast Between $30 to $95
CRISPR Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference
CRISPR Therapeutics AG (NASDAQ:CRSP) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
CRISPR Technology Market Report 2024, With Profiles of Major Players Agilent Technologies, Beam Therapeutics, Caribou Biosciences, Crispr Therapeutics, Danaher, Genscript, Lonza and More - ResearchAndMarkets.com
RBC Capital Reiterates Sector Perform on CRISPR Therapeutics, Maintains $53 Price Target